SCHEDULE: NorthStrive Fund II Exits Bluejay Diagnostics Position

NorthStrive Fund II LP and Manager Braeden Lichti have liquidated their entire stake in Bluejay Diagnostics, Inc., marking a complete exit from the company.

Summary

• NorthStrive Fund II LP and Braeden Lichti filed Amendment No. 1 to Schedule 13D on June 2, 2026.
• The reporting persons sold all previously owned shares of Bluejay Diagnostics common stock.
• Beneficial ownership has been reduced to 0 shares, representing 0.00% of the outstanding common stock.
• This filing serves as the final amendment and an official exit filing for the reporting group.
• The reporting persons previously held a stake exceeding 5% as of the original filing on March 11, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal, as a significant investor has completely liquidated their position, which is generally interpreted by the market as a lack of conviction in the company's value proposition.

Positives

• The reporting persons reported no legal proceedings or regulatory issues over the past five years.
• The exit simplifies the company's shareholder structure by removing a significant private fund holder.

Negatives

• A major shareholder has completely divested their interest, which often signals a lack of confidence in the company's future performance.
• The liquidation of a significant block of shares can create downward pressure on the stock price.
• The reporting persons ceased to be beneficial owners of more than five percent of the company's outstanding common stock.

Risks

• Potential for increased stock price volatility following the exit of a major stakeholder.
• Market perception of the exit may be negative, suggesting that former insiders or major holders no longer see value at current price levels.
• Loss of a significant institutional-style backer may impact the company's ability to attract future capital.

Future Outlook

The reporting persons have no further interest in the company and will no longer be required to file ownership updates unless they re-acquire a significant stake. The company must now navigate the market without the support of this major shareholder group.

Management Comments

• On June 2, 2026, Northstrive Fund sold all of its previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer.
• This filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

Industry Context

StockSavvy.ai notes that complete exits by major investment funds in the micro-cap diagnostics sector often precede or follow significant shifts in a company's strategic direction or financial stability, frequently occurring when clinical or commercial milestones are not met.

Comparison to Industry Standards

• Institutional exits in the diagnostics sector are common when capital requirements become too high relative to the expected return on investment.
• Compared to larger peers like QuidelOrtho or Exact Sciences, Bluejay Diagnostics is a much smaller entity where the exit of a single 5% holder has a disproportionate impact on market liquidity and investor sentiment.

Stakeholder Impact

• Shareholders may experience downward pressure on the stock price due to the liquidation of a large block of shares.
• Market sentiment may turn bearish following the exit of a major institutional investor.

Next Steps

• The reporting persons will cease filing ownership reports for Bluejay Diagnostics.
• Investors should monitor for any subsequent filings from other major shareholders or company insiders.

Key Dates

Recommendation

The total exit of a major shareholder who previously held a significant stake is a strong bearish signal. In the micro-cap space, such a move often suggests that the investor sees limited upside or significant upcoming risks that outweigh the potential for recovery.

Keywords

Bluejay Diagnostics, NorthStrive Fund II, Braeden Lichti, Schedule 13D, Divestment, Common Stock, Exit Filing, Beneficial Ownership